期刊文献+

布氏菌疫苗效力评价小鼠模型的建立

Establishment of the brucellosis vaccine potency evaluation model in mice
下载PDF
导出
摘要 目的建立布氏菌疫苗效力评价小鼠模型,为布氏菌疫苗有效性评价奠定基础。方法测定感染布氏菌株动物的脾脏细菌数,比较菌株毒力,筛选出布氏菌疫苗效力评价用布氏菌株。通过最小感染剂量的测定为效力评价的感染剂量提供基础数据。检测动物体内布氏菌增殖情况,确定动物解剖时间。将不同剂量的布氏菌活疫苗免疫小鼠,4周后用布氏菌强毒菌株皮下感染,感染4周后将动物解剖测定脾脏细菌数,分析疫苗保护效果。结果筛选出布氏菌疫苗效力评价感染用布氏菌株,该菌株的皮下最小感染剂量为300 CFU,感染后4周动物脾脏细菌数达到较高且稳定水平。布氏菌活疫苗免疫小鼠后能产生较好的保护效果,免疫剂量与保护力水平之间有较好的量效关系。结论建立了布氏菌疫苗效力评价小鼠模型,为新型布氏菌疫苗的研制奠定了基础。 Objective To develop and utilize appropriate animal model of Brucella infection in order to evaluate the efficacy of vaccines for human brucellosis. Methods The most virulent Brucella strain was selected by comparing the virulence. In order to establish the minimum infection dose of the selected Brucella strain in BALB/c mice, groups of 6 animals were injected with series concentration of Brucella bacteria. In order to determine the time of anatomy, mice were culled and the bacterial loads in the spleens were determined at different time after injection. Two experiments were performed to confirm and further characterize this mouse model. The mice were challenged with Brucella bacteria at 4 weeks after immunization, and the bacterial loads in the spleens were determined at 4 weeks after injection. Results The Brucella strain used for the evaluation of efficacy of brucellosis vaccine was selected, and the minimum infection dose of the selected Brucella XJ91-60 strain in BALB/c mice was 300 CFU. Bacterial loads in the spleen achieved high and stable level at 4 weeks after injection. The mice immunized with brucellosis vaccine were protected against challenge with virulent Brucella strain. Conclusion Brucellosis vaccine potency evaluation model in mice is established, which lays a foundation for the development of the new brucellosis vaccine.
作者 魏东 李天柱 陈成 尤明强 王国治 WEI Dong;LI Tian-zhu;CHEN Cheng;YOU Ming-qiang;WANG Guo-zhi(TB Vaccine Division,National Institute for Food and Drug Control,Key Laboratory of the Ministry of Health for Research on Quality and Standardization of Biotech Products,Beijing 100050,China;Second Bacterial Vaccine Division,Lanzhou Institute of Biological Products Co.,Ltd.,Lanzhou 730046,China)
出处 《中国医药生物技术》 2018年第5期418-421,共4页 Chinese Medicinal Biotechnology
基金 "重大新药创制"国家科技重大专项(2014ZX09304311-002)
关键词 布鲁杆菌菌苗 最小感染量 效力 Brucella vaccine Minimum infection dose Potency
  • 相关文献

参考文献5

二级参考文献26

  • 1PARANAVITANA C,ZELAZOW SKA E,IZAD-JOO M,et a1.Interferon-gamma associated cytokines and chemokines produced by spleen cells from Brucella-immune mice [J].Cytokine, 2005, 30: 86-92.
  • 2Hamdy M.E., S.M.El-Gibaly, andA.M.Montasser. Comparison between immune responses and resistance induced in BALB/c mice vaccinated withRB51 and Rev1 vaccines and challenged with Brucella melitensis bv.3[J]. Vet Microbiol, 2002, 88: 85-94.
  • 3Moriyon I, Grillo MJ, Monreal D, Gonzalez D, Marin C, et al. Rough vaccines in animal brucellosis: structural and genetic basis and present status. Vet Res ,2004,35: 1-38.
  • 4中华人民共和国兽用生物制品规程[M].二000年版.北京:化学工业出版社.154-160.
  • 5Davis DS, Elzer PH. Brucella vaccines in wildlife. Vet Microbiol, 2002, 90 (11): 533-544.
  • 6Bosseray N. Brucella melitensis Rev. 1 living attenuated vaccine: stability of markers, residual virulence and immunogenicity in mice. Biologicals, 1991, 19: 355–363.
  • 7Grillo MJ, Bosseray N, Blasco JM, et al. In vitro markers and biological activity in mice of seed lot strains and ommercial Brucella melitensis Rev 1 and Brucella abortus B19 vaccines. Biologicals, 2000, 28: 119–127.
  • 8崔步云.中国布鲁氏菌病疫情监测与控制[J].疾病监测,2007,22(10):649-651. 被引量:350
  • 9姜海,崔步云,赵鸿雁,朴东日,李兰玉.AMOS-PCR对布鲁氏菌种型鉴定的应用[J].中国人兽共患病学报,2009,25(2):107-109. 被引量:83
  • 10丁家波,张存帅,彭小兵,蒋颖,程君生,张尔利,蒋玉文,毛开荣.布鲁菌种属鉴定多重PCR方法的建立及初步应用[J].中国兽医学报,2009,29(5):594-597. 被引量:13

共引文献78

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部